Studies of HIV Eradication: a Case for Using NHP Models Guido Silvestri, MD Yerkes National Primate Research Center Emory University School of Medicine.

Slides:



Advertisements
Similar presentations
Pathogenesis of HIV disease and markers of progression Anjie Zhen, PhD.
Advertisements

New concepts in HIV: HIV immunopathogenesis, treatment and vaccine strategies - report back from pre-conference Nicolas Chomont VGTI-Florida.
Human Immunodeficiency Virus
Interactive Workshop “HIV Cure 101”: Challenges in identifying and targeting the HIV reservoir Sarah Palmer Centre for Virus Research Westmead Millennium.
Comparison between Pathogenic and Nonpathogenic SIV Infections and Focus on Mucosal Tissue Compartment Reveal a Critical Role for the.
ANIMAL MODELS HIV Cure Research Training Curriculum The HIV CURE training curriculum is a collaborative project aimed at making HIV cure research science.
Models Systems to Study HIV Emily L. Lowe, Ph.D. Microbiology, Immunology and Molecular Genetics UCLA.
Controversies in HIV Cure Research Debate 1. Is there ongoing replication under HAART? Mario Stevenson and Frank Maldarelli Moderator: Steve Deeks.
What can we learn from diverse spectrum of HIV/SIV infections? Françoise BARRÉ-SINOUSSI Regulation of Retroviral Infections Unit Department of Virology.
Immune deficiency Diseases (2). Immune Deficiency Disorders Immunodeficiencies can be divided into primary immunodeficiency disorders, and secondary immunodeficiency.
Over 50 million HIV/AIDS cases have occurred worldwide Over 40 million people are currently living with HIV/AIDS 95% of all cases are in developing countries.
IMMUNOLOGY PURSUIT General Immunology Specific Response Non Specific Response HIVDefinitions and Acronyms A0 B0 C0 D0 E0.
EARLY ANTIRETROVIRAL TREATMENT HIV Cure Research Training Curriculum (CUREiculum) Early Antiretroviral (ART) Treatment Module by: Scientific Leads: Dr.
Strategies for Targeting and Eradicating the HIV Reservoir
HIV Science Update from Rome to Addis : Basic Science Coumba Toure Kane Dakar University Senegal.
Pathogenesis of HIV disease and markers of progression Anjie Zhen, PhD.
Future directions in HIV basic science research The hunt for a cure.
Slide 1 of 10 From DC Douek, MD, at Atlanta, GA: April 10, 2013, IAS-USA. IAS–USA Daniel C. Douek, MD, PhD Bethesda, Maryland Immune Activation, HIV Persistence,
HIV/AIDS Isabelle Récaborde Dr. Frigon Chemistry SL – Block F Option - Medicine and Drugs.
Infections of the GI Tract November 19, 2007 NCDD Meeting Chair: Mitchell B. Cohen, MD Vice Chair: Richard S. Blumberg, MD.
Introduction to Basic Science Emily L. Lowe, Ph.D. Microbiology, Immunology and Molecular Genetics UCLA.
The HCV vaccine: cooperation in the shadow of the pyramids Antonella Folgori.
2014 “Towards an HIV Cure” Symposium Melbourne IL-21 reduces residual inflammation and virus persistence in ART-treated SIV- infected rhesus macaques Mirko.
Target cell availability dictates mother-to-infant transmission of SIV
Novel Approaches: Treatment and HIV Pathogenesis L. Trautmann, Ph.D. VGTI Florida.
HIV Cellular Pathogenesis III
Retrospective and Prospective U.S. Donor MRV Surveillance and Transmission Studies Michael Busch, MD, PhD Blood Systems Research Institute Dept of Laboratory.
Phylogenetic relationship of lentiviruses. - The heterologous host all develop disease that show many parallels to human AIDS, the similarities including.
KEY CONCEPT Some viral diseases can be prevented with vaccines.
Viral Tissue Reservoirs Are Determined Early and Little Viral RNA Is Detected during Suppression in the Macaque Model Zandrea Ambrose, Ph.D. Division of.
Immunology of HIV Infection Michael F. Para, MD Professor of Internal Medicine Division of Infectious Diseases 1 1.
After a virus becomes active and replicates in a host cell, it destroys the host cell. Copies of the virus are then released into the host organism, where.
Yerkes National Primate Research Center
Primary HIV-1 Infection Pathogenesis, Diagnosis, and Treatment Summary of Evidence Martin Markowitz M.D. Clinical Director and Staff Investigator Aaron.
Functional cure after long term HAART initiated during early HIV infection - a case study. van Lunzen J. 1,2, Schulze zur Wiesch J. 1,2, Schumacher U.
HIV Cellular Pathogenesis III Benhur Lee, M.D.. Adult v. infant (IgG v. IgA) CTL response (MHC tetramers) p24 antigenimia Ab response Viral load.
ANIMAL MODELS FOR HIV VACCINES Girish N. Vyas, Ph.D. UCSF School of Medicine, San Francisco (UCSF) A quote from the keynote Address at the January, 2008.
Question An Exception - Not Baboons Only 2 of 279 baboons in Tanzania and Ethiopia were found to harbor SIV Subsequently shown to be SIVagm.
SIVagm infection of rhesus macaques: a model of functional cure with persistent reservoirs of replication-competent virus Cristian Apetrei Center for Vaccine.
Future directions in HIV basic science research The hunt for a cure.
What are possible biomarkers for cure-related interventions ? Lars Ostergaard, MD, Ph.D., DMSc Prof/Head Dept of infectious diseases Aarhus.
ImmunoPathogenesis of HIV Disease Overview of HIV Epidemic Basic biology of HIV-1 Stages of HIV Disease Viral and Cellular Dynamics after HAART HIV Therapy.
HBV (chronic) HIV ~400 million chronically infected
IAS Members Meeting July 19th 2011 Achievements and learning over the past 30 years: what do we need next? Françoise BARRÉ-SINOUSSI Regulation of Retroviral.
HIV pathogenesis The course of HIV infection 1. Acute Phase 2. Intermediate (asymptomatic) phase -viral load stabilizes at a “set point”. 3. Late (symptomatic)
Cancers of the Digestive System November 19, 2007 NCDD Meeting Chair: John M. Carethers, MD Vice Chair: Robert Sandler, MD, MPH.
25 Years of HIV Vaccine Research: What have we accomplished? José Esparza MD, PhD Senior Advisor on HIV Vaccines Global Health Program The Search for an.
1 Adherence to ARV Therapy and Resistance HAIVN Havard Medical School AIDS Initiative in Vietnam.
The Future of HIV/AIDS: The Road to a Cure. How HIV persists during therapy?  Ongoing viral replication occurs in subjects on suppressive HAART (TW Chun,
Track A Orientation Guido Silvestri, M.D. Track A Co-Chair
Immune reconstitution Anjie Zhen, PhD
HUMAN IMMUNODEFICIENCY VIRUS AND ACQUIRED IMMUNODEFICIENCY SYNDROME (AIDS)
HUMORAL IMMUNE RESPONSES HAVE LITTLE EFFECT ON CONTROLLING VIREMIA DURING SIVagm INFECTION OF AFRICAN GREEN MONKEYS Thaidra Gaufin Division of Microbiology.
HAART Initiation Within 2 Weeks of Seroconversion Associated With Virologic and Immunologic Benefits Slideset on: Hecht FM, Wang L, Collier A, et al. A.
The impact of treatment duration on defective and expanded identical HIV genomes in T cell subsets from peripheral blood and tissues Eunok Lee.
State of HIV Cure Research
HIV Cure: Current Status and Future Perspectives
Human Immunodeficiency virus HIV Retroviridae R
The course of HIV infection
Christine M. Fennessey, Ph.D AIDS and Cancer Virus Program
Immunodeficiency (2 of 2)
Hiv.
Coinfection With HIV-1 and HCV—A One-Two Punch
Reservoir Host Immune Responses to Emerging Zoonotic Viruses
Jason M. Brenchley, Guido Silvestri, Daniel C. Douek  Immunity 
Immunodeficiency (2 of 2)
Hunting Down the HIV-1 Reservoir: A Starring Role for Antibodies?
Study of HIV-2 in monkey Pigtail macaque (Macaca nemestrina) Baboons
Coinfection With HIV-1 and HCV—A One-Two Punch
Keep control: Elite and post-treatment controllers
Presentation transcript:

Studies of HIV Eradication: a Case for Using NHP Models Guido Silvestri, MD Yerkes National Primate Research Center Emory University School of Medicine Emory Center for AIDS Research (CFAR) Emory Vaccine Center

Similarities between HIV & pathogenic SIV infection of macaques 1.Chronic progressive infection associated with opportunistic infections and CNS disease (simian AIDS). 2.Instances of “benign” cases (LTNP, EC) associated with low viremia and specific MHC Class-I alleles. 3.Kinetics of viremia characterized by acute peak and post-peak decline. 4.Presence of vigorous but ultimately ineffective innate and adaptive immune responses to the virus. 5.Key pathogenic events include chronic immune activation, mucosal immune dysfunction, microbial translocation, and high levels of infection of central-memory CD4+ T cells. 6.Virus replication can be suppressed by ART with persisting reservoirs of latently infected cells. Perhaps the best animal model available for any human disease?

Historical Results 1.Studies of the very early events of virus transmission and dissemination. 2.Detailed immunological and virological analyses of the acute phase of infection. 3.Characterization of the basic pathogenic events in tissues. 4.Definition of the in vivo role of specific viral proteins (i.e. delta Nef viruses etc) 5.Assessment of the role of the host immune response in controlling virus replication by using “depletion” techniques. 6.Studies of pathogenesis using “invasive” techniques (i.e., repeated tissue sampling, cell labeling techniques, etc). 7.Pre-clinical testing of candidate AIDS vaccines, microbicides, and antiretroviral strategies. The model is vastly under-utilized for studies of HIV eradication

Opportunities provided by the NHP models in studies of HIV eradication 1.Extensive characterization of the virus in tissues (including elective necropsy). 2.Pilot trials of in vivo eradication conducted in a timely and controlled fashion. 3.Testing of “risky” interventions (i.e., cell depletion experiments, stem cell-based interventions etc) 4.Control for various clinical parameters that are virtually impossible to control in humans (time of infection, duration of ART etc). Currently, key limitations to this type of studies are their cost and the lack of standardized resources.

Do we need a standardized NHP resource? 1.Currently every investigators who wishes to study HIV eradication in NHPs has to build (or even invent) her/his own resource– this situation may discourage scientists to get into “eradication” work in primates. 2.Standardizing the model(s) in terms of species, virus, type and timing of treatment, assays, veterinarian techniques, etc., may allow for better comparison between proposed interventions. 3.A standardized NHP resource could also save money due to simple economy of scale. What NHP model should be used?

Rhesus Macaque Models of HIV Infection From Ruprecht R. and Silvestri G, Curr Opin Virol, in press